Remission of alcohol use disorder following traumatic brain injury with focal orbitofrontal cortex hemorrhage: case report and network mapping

Introduction

Joutsa et al.1 study in Nature Medicine demonstrated that brain lesions disrupting addictive behavior can be mapped to a common brain network. Their analysis included two cohorts of patients with remission of smoking following focal brain damage (primarily stroke). Concurrently, preclinical research is building circuit models for drug-addictive behavior that have identified overlapping hotspots including the orbitofrontal cortex (OFC)2. Here we describe a case of a patient whose alcohol use disorder (AUD) went into remission after a traumatic brain injury (TBI) with focal left OFC intracerebral hemorrhage. To the best of our knowledge, there have been no published reports of focal lesions resulting in remission of isolated AUD (without polysubstance use). Furthermore, we believe that our case complements the recent network mapping study and adds to our understanding of the critical role of the OFC in models of addictive behavior.

In this report, we describe and analyze the case lesion and find that its network map converges on the same topography established in previously described addictive behavior lesion network mapping1, but with an inverse connectivity profile.

Methods

Case

Ms. B is a 42-year-old woman with a chronic history of treatment-refractory AUD, depression, and post-traumatic stress disorder (PTSD). Previous attempts to reduce alcohol consumption were unsuccessful despite multiple psychosocial (group support and individual counseling) and pharmacological treatment trials (gabapentin, naltrexone). Problematic alcohol use first began in her early 20s following a depressive episode, with further escalation of alcohol use in her 30s in the context of an abusive relationship. Ms. B’s baseline alcohol consumption prior to her presentation consisted of two bottles of wine per day. She denied any other substance use. She lives alone and runs a small business.

One month prior to assessment in the clinic, Ms. B suffered a TBI after falling downstairs while intoxicated by alcohol. She struck her head and lost consciousness with no memory of the incident. Her Glasgow Coma Scale (GCS) was 14 on the initial trauma evaluation in the emergency department at Sunnybrook Health Sciences Center. She reported headaches, confusion, and dizziness. There was no seizure activity. On examination, she was grossly cognitively intact and had no evidence of focal neurological deficits. Laboratory investigations noted an elevated ethanol level of 86 mg/dL but were otherwise unremarkable.

A motion-degraded CT head demonstrated trace subarachnoid hemorrhage (SAH) along the left anterior temporal lobe with a possible associated thin extra-axial hematoma and small contusion (Fig. 1a). She was admitted to the Intensive Care Unit for neuromonitoring and CIWA protocol. A repeat CT head the next day revealed a new 1 cm, well-circumscribed intracerebral hemorrhagic contusion localizing to the left OFC (Fig. 1a). The previously reported extra-axial hematoma and SAH were less conspicuous. A third CT scan the following day showed only the stable 1 cm OFC hematoma with mild surrounding edema, no other abnormalities were reported (Fig. 1a).

Fig. 1: Case lesion and lesion network.
figure 1

a CT head (axial slices) post-traumatic brain injury: (i) Initial scan in ER revealing trace subarachnoid hemorrhage (SAH) along the left anterior temporal lobe (yellow arrow) with a possible associated thin extra-axial hematoma and small contusion, (ii) Day 2 scan showing a 1 cm, well-circumscribed left orbitofrontal cortex intracerebral hemorrhage (red arrow), (iii) Day 3 scan showing stable focal hemorrhage (red arrow) with mild surrounding edema, (iv) One-month follow-up scan showing resolution of intracranial hemorrhages and no acute abnormalities. b Lesion location was traced and delineated on the MNI space template brain. c The MNI space lesion was used to compute functional connectivity to all brain voxels. This map was compared to the smoking addictive behavior network described by Joutsa et al. presented in (d). Color scales represent t values.

Full size image

At assessment in our TBI clinic a few weeks after the injury, Ms. B reported improvement in her symptoms of headache and dizziness but persistent anosmia/ageusia, insomnia, and mild short-term memory difficulties. She denied any focal neurological deficits, and the neurological exam was unremarkable. Interestingly, Ms. B reported a dramatic cessation of her cravings and interest in drinking alcohol after the TBI. This translated to her being abstinent from alcohol for the first time in years. At the time, she continued to take gabapentin prescribed for her alcohol dependence (on a stable dose prior to TBI) and had stopped taking naltrexone two weeks prior to her TBI as she did not perceive any benefit. She has not begun any new medications since the TBI. Shortly after her initial hospitalization, she returned to working full-time and was functionally independent.

Follow-up neuroimaging approximately 1 month after the TBI showed resolution of her focal left OFC hemorrhage. It was reported as normal except for mild cerebellar atrophy believed to be secondary to her chronic alcohol use (Fig. 1a). At 1-year follow-up, she reported one relapse a few months after the TBI that was triggered by increased workplace stressors (in the context of the COVID pandemic). After the relapse, she successfully abstained from alcohol in the four months preceding her 1-year follow-up in our clinic (early remission). She was discharged from the TBI clinic.

Written informed consent for publication of clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal. This is a case report, and thus, institutional research ethics approval was not required.

Network mapping

To further analyze how this left OFC hemorrhagic TBI lesion could have potentially contributed to remission of treatment-refractory AUD, we collaborated with Joutsa and colleagues to identify the brain circuits affected by the lesion.

The lesion was traced and delineated in a Montreal Neurological Institute (MNI) space template brain (Fig. 1b). Functional connectivity from the lesion location to all brain voxels was computed using an external connectome created from resting state functional connectivity imaging data from 1000 healthy volunteers, as in the original study1.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Results

Network mapping

The case lesion was strongly functionally connected to the ventral prefrontal and temporal cortices (positive connectivity) and the insula and operculum (negative connectivity), but the direction of connectivity to these regions was the opposite compared to Joutsa and colleagues’ smoking addictive behavior remission map (spatial correlation r = −0.59) (Fig. 1c, d).

To test if this correlation was more negative than what would be expected by chance, the spatial correlation coefficient was compared to null distribution created by 10,000 iterations randomly permuting group labels, recomputing the smoking addictive behavior remission map, and then recomputing the spatial correlation with our case1. This analysis showed that the spatial correlation between the case and addictive behavior remission maps was significantly lower than what would be expected by chance (permutation test 1-sided, p = 0.04). In addition, to test if the spatial correlation was lower than that with random stroke lesion connectivity maps, the spatial correlation was compared to that of 200 random stroke cases using Wilcoxon signed rank test, showing that the correlation was lower than that of the random stroke cases (1-sided, z = 12.21, p < 0.001).

Discussion

TBI results from a force transmitted to the head that causes neuropathologic damage and/or dysfunction. Unlike stroke that typically results in discrete region(s) of infarction and is often considered a gold standard for lesion data, TBI can be more complicated to interpret as it can result in diffuse and/or focal damage with heterogenous pathology3.

Joutsa and colleagues used lesion network mapping to identify a connectivity profile mediating remission from smoking addictive behavior1. They also showed that lesions associated with reduced alcoholism risk had a similar connectivity profile suggesting that the findings may generalize to other substance use disorders1. The present case demonstrates that a TBI hemorrhagic lesion resulting in early remission of AUD converges on the same network topography but with an inverse connectivity profile (i.e. positive connectivity to the negative nodes and negative connectivity to the positive nodes of the addictive behavior remission network). Given this finding, it is possible that just disrupting the network, regardless of the direction of the effect, would be sufficient to facilitate addictive behavior remission. This hypothesis would be in keeping with recent work demonstrating that targeting the same symptoms with mechanisms increasing focal brain activity, such as high-frequency repetitive Transcranial Magnetic Stimulation (rTMS), and decreasing focal brain activity, such as a lesion or low-frequency rTMS, converge on the common network but with opposing connectivity profiles4, and effects of DBS that clinically represent therapeutic lesions but are associated with increased blood flow and glucose metabolism at the stimulation site5. Alternatively, if the case lesion was potentially excitatory (rather than a traditional lesion exerting inhibitory effects), then the connectivity profile would align closely with the addictive behavior remission map. Though hemorrhages can induce hyper-excitable brain states (e.g., seizures), we have no supportive data in the present case to corroborate this possibility and this remains speculative.

The OFC is located along the ventral aspect of the prefrontal cortex and is a primary node in executive function networks with strong connections to the medial prefrontal cortex, dorsal striatum, amygdala, and brainstem6. Integrating sensory information and reward-related stimuli for the purpose of evaluating choices is a particularly critical role of the OFC6. Accordingly, the OFC has been implicated in the pathophysiology of addictive behavior/AUD, including the regulation of urges, compulsions, and reward decision-making processes6. Addictive drugs initially target the mesolimbic system and evoke strong dopamine transients in the nucleus accumbens; however, in individuals where compulsion emerges, excitatory projections from the OFC to the dorsal striatum become potentiated7 and this affects both the direct and indirect pathways within the basal ganglia8. Based on these findings, depotentiation of excitatory afferents, or as in the case of a focal lesion, a loss of function would be beneficial for addictive behavior remission.

The intersection of TBI and AUD is complex and given that this is a case report, we were unable to control for other variables that could be relevant to our patient’s remission. This may include cognitive factors related to realization that alcohol consumption/intoxication may have contributed to the TBI, physical barriers such as injury preventing ability to acquire and consume alcohol post TBI or, social factors including financial constraints in accessing alcohol9. The latter two variables were not relevant in our case. Other factors, such as less social interaction or reduced exposure to triggers for alcohol use in the context of recovery from TBI, could have been potential contributors to remission. Her persistent anosmia and ageusia post TBI could have also been a factor impacting her reduced alcohol consumption, but she did not directly cite this as playing a role10. The role of psychiatric symptoms, which often intersect with alcohol consumption, potentially influenced this patient’s alcohol use. It is possible that improvement in symptoms of depression and PTSD could have contributed to this patient’s remission. However, this is not known in our case. It is not uncommon that in the immediate period after a moderate-to-severe TBI, patients with a prior history of AUD reduce their alcohol intake; however, alcohol intake can then subsequently increase with time post TBI9. Another limitation is that potential post-TBI diffuse axonal injury (DAI) and microstructural changes may be present and not be directly observable with standard clinical neuroimaging. It is also important to consider that the OFC injury may have interacted with networks involved in affective dysregulation, and indirectly impacted alcohol use through reduced psychiatric symptom burden. Advanced neuroimaging in research settings suggests that DAI may disrupt large-scale connectivity networks including the default mode and salience networks11 relevant to addictive behavior. Given the limitations in quantifying the presence/extent of DAI and/or diffuse functional network changes in clinical practice, we need to consider TBI as a mechanism generating an isolated focal lesion(s) cautiously.

Related Articles

Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via IL-10-dependent Treg–microglia crosstalk

Neuroinflammation plays a crucial role in traumatic brain injury (TBI), contributing to both damage and recovery, yet no effective therapy exists to mitigate central nervous system (CNS) injury and promote recovery after TBI. In the present study, we found that nasal administration of an anti-CD3 monoclonal antibody ameliorated CNS damage and behavioral deficits in a mouse model of contusional TBI. Nasal anti-CD3 induced a population of interleukin (IL)-10-producing regulatory T cells (Treg cells) that migrated to the brain and closely contacted microglia. Treg cells directly reduced chronic microglia inflammation and regulated their phagocytic function in an IL-10-dependent manner. Blocking the IL-10 receptor globally or specifically on microglia in vivo abrogated the beneficial effects of nasal anti-CD3. However, the adoptive transfer of IL-10-producing Treg cells to TBI-injured mice restored these beneficial effects by enhancing microglial phagocytic capacity and reducing microglia-induced neuroinflammation. These findings suggest that nasal anti-CD3 represents a promising new therapeutic approach for treating TBI and potentially other forms of acute brain injury.

Zipper-interacting protein kinase mediates neuronal cell death and cognitive dysfunction in traumatic brain injury via regulating DEDD

Neuronal cell death is a causative process in traumatic brain injury (TBI)-induced structural and functional impairment of the central nervous system. However, the upstream trigger of TBI-induced neuronal loss and the underlying molecular pathways remain unclear. Zipper-interacting protein kinase (ZIPK) has been shown to be upregulated in Alzheimer’s disease and ischemic stroke and to play a role in cellular apoptosis, while its pathological significance in TBI has not been reported. Herein, we discovered for the first time that ZIPK expression was markedly elevated in neurons after TBI and that ZIPK caused massive neuronal apoptosis in peri-contusional brain regions. Zipk haploinsufficiency antagonized neuronal cell death and reversed several typical neuropathological changes induced by TBI. Mechanistically, we found that ZIPK affected neuronal viability by modulating death effector domain-containing DNA binding protein (DEDD) and caspase-3 pathway. Specifically, ZIPK could bind to and phosphorylate DEDD at the S9 residue, thus enhancing the stability of DEDD, and leading to the activation of caspase-3-mediated apoptotic cascade in neurons. The rescue of neuronal loss by ZIPK downregulation effectively alleviated TBI-induced behavioral deficits by preserving motor and cognitive abilities in vivo, supporting the decisive role of ZIPK dysregulation in TBI-associated neuronal dysfunctions by modulating neuronal survival. Furthermore, pharmacological suppression of ZIPK activity by a specific inhibitor prior to TBI protected neurons from brain injury-induced cell death and neuronal degeneration in vitro and in vivo by preventing DEDD upregulation and caspase-3 activation. In conclusion, our data reveal the essential contribution of ZIPK to TBI-induced neuronal cell death through the DEDD/caspase-3 cascade, and suggest the potential of targeting ZIPK as an effective strategy for treating TBI-related neuropathologies.

NINJ1-mediated plasma membrane rupture of pyroptotic endothelial cells exacerbates blood-brain barrier destruction caused by neutrophil extracellular traps in traumatic brain injury

Brain endothelial cell (bEC) dysfunction is the main factor of blood-brain barrier (BBB) breakdown, which triggers a vicious cycle of aggravating traumatic brain injury (TBI) pathogenesis. Previous studies have revealed that neutrophil extracellular traps (NETs) released by neutrophils can lead to BBB disruption, but there is a lack of research on the underlying mechanisms after TBI. Here, excessive NETs were found in both contused brain tissue and circulation following TBI. We found that NETs could activate the TLR4/NF-κB pathway to induce bEC pyroptosis, which led to BBB disruption after TBI. During this process, ninjurin-1 (NINJ1) was activated in pyroptotic bECs, and it mediated the release of high mobility group box 1 protein (HMGB1) via plasma membrane rupture (PMR) to promote NET formation. NINJ1-mediated release of HMGB1 aggravated NET accumulation by forming a vicious circle following TBI. Knockdown of NINJ1 rescued NET formation, attenuated BBB leakage, and improved neurological outcomes after TBI. NINJ1 may represent a promising target for alleviating NET-induced BBB destruction and other related injuries after TBI.

Genetic deletion of G protein-coupled receptor 56 aggravates traumatic brain injury through the microglial CCL3/4/5 upregulation targeted to CCR5

Traumatic brain injury (TBI) is a significant global health concern that often results in death or disability, and effective pharmacological treatments are lacking. G protein-coupled receptor 56 (GPR56), a potential drug target, is crucial for neuronal and glial cell function and therefore plays important roles in various neurological diseases. Here, we investigated the potential role and mechanism of GPR56 in TBI-related damage to gain new insights into the pharmacological treatment of TBI. Our study revealed that TBI caused a significant decrease in GPR56 expression and that the deletion of Gpr56 exacerbated neurological function deficits and blood‒brain barrier (BBB) damage following TBI. Additionally, Gpr56 deletion led to increased microgliosis, increased infiltration of peripheral T cells and macrophages, and increased release of cerebral inflammatory cytokines and chemokines after TBI. Furthermore, Gpr56 deletion induced neuronal apoptosis, impaired autophagy, and exacerbated neurological function deficits through microglial-to-neuronal CCR5 signaling after TBI. Overall, these results indicate that Gpr56 knockout exacerbates neurological deficits, neuroinflammation and neuronal apoptosis following TBI through microglial CCL3/4/5 upregulation targeted to CCR5, which indicates that GRP56 may be a potential new pharmacological target for TBI.

Responses

Your email address will not be published. Required fields are marked *